Medscape is available in 5 Language Editions – Choose your Edition here.


Short-Bowel Syndrome

  • Author: Burt Cagir, MD, FACS; Chief Editor: John Geibel, MD, DSc, MSc, MA  more...
Updated: Dec 02, 2015


Each year in the United States, many patients undergo resection of long segments of small intestine for various disorders, including inflammatory bowel disease (IBD), malignancy, mesenteric ischemia, and others. Juvenile survivors of necrotizing enterocolitis, midgut volvulus, and other abdominal catastrophes are becoming more common. Various nonoperative procedures can leave patients with a functional short-bowel syndrome. An example of this clinical scenario is radiation enteritis.

Those patients who are left with insufficient small bowel absorptive surface area develop malabsorption, malnutrition, diarrhea, and electrolyte abnormalities. The subset of patients with clinically significant malabsorption and malnutrition are said to have developed short-bowel syndrome.

The average length of the adult human small intestine is approximately 600 cm, as calculated from studies performed on cadavers. According to Lennard-Jones and to Weser, the range extends from 260 to 800 cm.[1] Any disease, traumatic injury, vascular accident, or other pathology that leaves less than 200 cm of viable small bowel or results in a loss of 50% or more of the small intestine places the patient at risk for developing short-bowel syndrome.

Short-bowel syndrome is a disorder clinically defined by malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. The final common etiologic factor in all causes of short-bowel syndrome is the functional or anatomic loss of extensive segments of small intestine so that absorptive capacity is severely compromised. Although resection of the colon alone typically does not result in short-bowel syndrome, the condition's presence can be a critical factor in the management of patients who lose significant amounts of small intestine.[2, 3]

Massive small intestinal resection compromises digestive and absorptive processes. Adequate digestion and absorption cannot take place, and proper nutritional status cannot be maintained without supportive care. Today, the most common causes of short-bowel syndrome in adults include Crohn disease,[4] radiation enteritis, mesenteric vascular accidents, trauma, and recurrent intestinal obstruction. In the pediatric population, necrotizing enterocolitis, intestinal atresias, and intestinal volvulus are the most common etiologic factors.

Other conditions associated with short-bowel syndrome include congenital short small bowel, gastroschisis, and meconium peritonitis.

Not all patients with loss of significant amounts of small intestine develop short-bowel syndrome. Important cofactors that help to determine whether the syndrome will develop or not include the premorbid length of small bowel, the segment of intestine that is lost, the age of the patient at the time of bowel loss, the remaining length of small bowel and colon, and the presence or absence of the ileocecal valve.

Several operative or invasive procedures and therapies have been designed for and applied to the treatment of short-bowel syndrome. These include the establishment of central venous access for delivery of total parenteral nutrition (TPN), intestinal transplantation, and nontransplantation abdominal operations. The history of these various treatment strategies is discussed in this section.

TPN was developed successfully by Dudrick et al.[5] Their landmark paper included laboratory studies in a canine model and clinical results in 30 adult patients with a variety of gastrointestinal (GI) maladies ranging from achalasia to traumatic pancreatitis to regional enteritis. The animal model clearly demonstrated efficacy. Beagle puppies fed entirely intravenously surpassed their littermate controls in weight gain and were equal in terms of activity level, skeletal growth, and other developmental landmarks.

In the clinical arm of the study,[5] the 30 subjects receiving TPN were able to achieve positive nitrogen balance, maintain weight, heal wounds, and close fistulae. Wilmore and Dudrick reported positive nitrogen balance, growth, and development in an infant born with diffusely atretic small bowel who was fed entirely parenterally.[6]

After these initial successes, the new technique was introduced into the clinical mainstream, and indications for its use have expanded tremendously. Patients with short-bowel syndrome are now routinely treated with TPN, especially early in their course. New therapeutic strategies that may allow patients to discontinue or curtail the use of TPN are discussed in subsequent sections.

Numerous nontransplant operative approaches have been used in the treatment of patients with short-bowel syndrome. The creation of reversed intestinal segments was popular in the 1960s and 1970s. The aim of this operation was to produce a sort of functional partial small-bowel obstruction that would slow intestinal transit time, thereby encouraging greater nutrient absorption and decreasing diarrhea and nutrient loss.

Around that time, recirculating small bowel loops were also being created, with the same idea in mind. The results were mixed to questionable, and these procedures are rarely used today. Intestinal lengthening (Bianchi procedure), the creation of artificial enteric valves, strictureplasty, and intestinal tapering procedures continue to be employed at some centers today.

Intestinal transplantation was first attempted in dogs in 1959. The procedures failed because of the great concentration of immune system cells associated with the gut. The discovery and clinical implementation of powerful immunosuppressive drugs, such as FK506 (tacrolimus) and cyclosporine A, made successful small bowel transplantation possible.

The first successful combined transplantation of small intestine and liver in a human was performed in 1990. Since that time, the technique of isolated small intestinal transplantation has been developed and applied. Better graft survival rates are achieved when patients receive their transplant before complications secondary to short-gut syndrome occur, especially that of cirrhosis.[7]



The duodenum extends from the pylorus to the duodenojejunal flexure and is about 25 cm in overall length.[8] At the upper left border of the second lumbar vertebra is the duodenojejunal flexure. Here the duodenum turns anteriorly and caudally to become the jejunum just distal to the ligament of Treitz.

The small bowel is divided relatively arbitrarily into the jejunum (the proximal two fifths) and ileum (the distal three fifths), though grossly the jejunum may appear to be of greater caliber, with a slightly thicker wall. It is fixed to the retroperitoneum by the root of the mesentery, which extends from the left upper quadrant of the abdomen to the right lower quadrant.

The terminal ileum is located in the right lower quadrant. The ileocecal valve marks the transition from small intestine to large intestine. The first portion of the colon is called the cecum. The ascending colon climbs along the right paracolic gutter and bends toward the midline at the hepatic flexure. Here, the transverse colon begins and makes its way to the splenic flexure, where the colon angles slightly medially and also inferiorly to become the descending colon.

As the descending colon crosses the pelvic brim, it becomes the sinuous sigmoid colon. This portion of the colon heads toward the midline and then proceeds inferiorly. Below the pelvic peritoneal reflection, the sigmoid colon becomes the rectum.

The blood supply to the duodenum is extensive and is derived from branches of both the celiac axis and the superior mesenteric artery. These include, but are not limited to, the gastroduodenal artery, the superior and inferior pancreaticoduodenal arteries, the right gastroepiploic artery, and the supraduodenal and retroduodenal arteries. This dual blood supply helps to preserve the duodenum in the event of sudden occlusion of the superior mesenteric artery.

Although their blood supply is rich, the jejunum, with the exception of its proximal few centimeters, and ileum depend solely on branches of the superior mesenteric artery. These are termed the jejunal and ileal, or intestinal, arteries. The ileocolic artery, a branch of the superior mesenteric artery, also supplies the terminal ileum.

The ileocolic artery and the right colic artery supply the cecum and the ascending colon. The dominant blood supply of the proximal two thirds of the transverse colon is the middle colic artery. All of these colic arteries are branches of the superior mesenteric artery. Thus, the entire midgut, from jejunum to mid transverse colon, is dependent on the superior mesenteric artery.

Branches of the left colic artery, which is derived from the inferior mesenteric artery, supply the distal transverse colon and the descending colon. The sigmoid arteries and the superior rectal artery are derived from the inferior mesenteric artery as well.

For an exhaustive exegesis on the anatomy and the techniques of multivisceral abdominal organ transplantation, see The Many Faces of Multivisceral Transplantation by Starzl et al.[9]



Physiologic derangements in short-bowel syndrome are the result of the loss of large amounts of intestinal absorptive surface area. The sequelae of this loss include malabsorption of water, electrolytes, macronutrients (ie, proteins, carbohydrates, fats), and micronutrients (ie, vitamins, minerals, trace elements).

The GI tract is a vital locus for water and electrolyte absorption and transport. In addition to managing exogenously obtained sources of these nutrients, such as daily water intake and the electrolytes found in liquid and solid foods, the GI tract must deal with its own considerable daily secretions.

The monumental nature and efficiency of this task is illustrated by Sellin,[10] who notes that the GI tract processes 8000-9000 mL of fluid per day, with the vast majority of this derived from endogenous secretions. Fluid reabsorption by the healthy GI tract is efficient (98%), and only 100-200 mL are lost in fecal matter each day. The great majority (80%) of this reabsorption occurs in the small intestine.

Disturbances in the major determinants of intestinal fluid absorption negatively impact the ability to reabsorb this large fluid load. The major determinants include intestinal mucosal surface area, the health or integrity of the mucosa, the status of small bowel motility, and the osmolarity of solutes in the intestinal lumen.

Clinically, these disturbances can manifest as major components of short-bowel syndrome, namely diarrhea, dehydration, and electrolyte imbalance. Thus, short-bowel syndrome can be produced by clinical entities that result in critical loss of mucosal surface area (eg, massive small-bowel resection) or degrade mucosal integrity (eg, radiation enteritis).

Macronutrients and micronutrients are absorbed along the length of the small intestine. However, the jejunum has taller villi, deeper crypts, and greater enzyme activity than the ileum.[11] Therefore, under normal conditions, about 90% of digestion and absorption of significant macronutrients and micronutrients are accomplished in the proximal 100-150 cm of the jejunum.[12, 13] This includes absorption of proteins; carbohydrates; fats; vitamins B, C, and folic acid; and the fat-soluble vitamins A, D, E, and K.

However, if a significant portion or all of the jejunum is resected, the absorption of proteins, carbohydrates, and most vitamins and minerals can be unaffected because of adaptation in the ileum. Unfortunately, enzymatic digestion suffers because of the irreplaceable loss of enteric hormones produced by the jejunum. Biliary and pancreatic secretions decrease. Gastrin levels rise, causing gastric hypersecretion. The resultant high acid output from the stomach may injure the small bowel mucosa.

Additionally, the low intraluminal pH creates unfavorable conditions for optimal activity of the pancreatic enzymes that are present. Diarrhea may then result if a large osmotically active solute load of unabsorbed nutrients is delivered to the ileum and colon.

Ileal resection severely decreases the capacity to absorb water and electrolytes. In addition, the terminal ileum is the site of absorption of bile salts and vitamin B12. Loss of significant lengths of ileum almost invariably results in diarrhea. Continued loss of bile salts following resection of the terminal ileum leads to fat malabsorption, steatorrhea, and loss of fat-soluble vitamins.

Retention of the ileocecal valve plays a pivotal role in massive small bowel resection. If the ileocecal valve can be preserved, intestinal transit is slowed, allowing more time for absorption. If the ileocecal valve is lost, transit time is faster, and loss of fluid and nutrients is greater. Furthermore, colonic bacteria can colonize the small bowel, worsening diarrhea and nutrient loss.

Preservation of the colon has positive and negative attributes. Philips and Giller demonstrated that colonic water absorption could be increased to as much as five times its normal capacity following small bowel resection.[14]

Also, by virtue of its resident bacteria, the colon has the inherent capacity to metabolize undigested carbohydrates into short-chain fatty acids, such as butyrate, propionate, and acetate. These are a preferred fuel source for the colon. Interestingly, work by Pomare and colleagues and Halverstad demonstrated that the colon can absorb up to 500 kcal daily of these metabolites, which then can be transported via the portal vein to be used as a somatic fuel source.[15]

In contrast, maintenance of the colon increases the incidence of urinary calcium oxalate stone formation. Oxalate is normally bound by calcium in the small bowel and thus is insoluble when it reaches the colon. After massive enterectomy, much of this calcium is bound by free intraluminal fats. Free oxalate is delivered to the colon, where it is absorbed. This can eventually lead to saturation of the urine with calcium oxalate crystals and result in stone formation. Retention of the colon in the absence of a competent ileocecal valve can lead to small intestinal bacterial overgrowth.

The physiologic changes and adaptation of patients with short-bowel syndrome can be viewed in three phases.[16]

The acute phase occurs immediately after massive bowel resection and may last up to 3-4 months. it is associated with malnutrition and fluid and electrolyte loss through the GI tract. Fluid and electrolyte loss through the GI tract may be as high as 6-8 L/day. Patients will have abnormal liver function test results and transient hyperbilirubinemia.

Enteral feedings may also be initiated, but it should be relatively slow. Patients with less than 100 cm of small intestine will require TPN. The presence of ileocecal valve or colon may play a significant role in the outcome of these patients.[16]

The adaptation phase generally begins 2-4 days after bowel resection and may last up to 12-18 months.[16] During this second phase, up to 90% of the bowel adaptation may occur. Villous hyperplasia, increased crypt depth, and intestinal dilatation occur. Early continuous feedings with a high viscosity elemental diet may reduce the duration of TPN.[16]

In the maintenance phase, the absorptive capacity of the GI tract is at its maximum.[16] Some patients may still require TPN. In other patients, nutritional and metabolic homeostasis can be achieved by small meals and supplemental nutritional support for life. These patients will also require vitamins and mineral supplements, including vitamins A, B12, and D, magnesium, and zinc.[16]

To summarize, the acute phase has the following characteristics:

  • Starts immediately after bowel resection and lasts 1-3 months
  • Ostomy output of greater than 5 L/day
  • Life-threatening dehydration and electrolyte imbalances
  • Extremely poor absorption of all nutrients
  • Development of hypergastrinemia and hyperbilirubinemia

The adaptation phase has the following characteristics:

  • Begins within 48 hours of resection and lasts up to 1-2 years
  • Approximately 90% of the bowel adaptation takes place during this phase
  • Enterocyte hyperplasia, villous hyperplasia, and increased crypt depth occur, resulting in increased surface area; intestinal dilatation and lengthening also occur
  • Luminal nutrition is essential for adaptation and should be initiated as early as possible; parenteral nutrition is also essential throughout this period

The maintenance phase has the following characteristics:

  • The absorptive capacity of the intestine is at its maximum
  • Nutritional and metabolic homeostasis can be achieved by oral feeding, or patients are committed to receiving supplemental or complete nutritional support for life


In the first decades of the twentieth century, bowel strangulation and midgut volvulus were the most common etiologies resulting in short-bowel syndrome. By the 1950s and 1960s, mesenteric vascular accidents, including thrombosis and embolism of the superior mesenteric artery, had become the most common causes of short-bowel syndrome.

Jejunoileal bypass procedures once were popular for the treatment of morbid obesity. However, they produced an iatrogenic short-gut syndrome and the attendant metabolic and hepatic complications associated with chronic malabsorption. These procedures have since been abandoned.

Studies by Ladefoged and colleagues and Nightingale and Lennard-Jones found that Crohn disease has become the most common etiology of short-bowel syndrome in adults, accounting for 50-60% of cases.[17, 18] Other important causative entities include mesenteric ischemia and radiation enteritis.

In contrast, the Spanish home parenteral nutrition registry data reported by Moreno and colleagues described mesenteric ischemia as the leading cause of short-bowel syndrome (29.7%), followed by neoplastic diseases (16.2%), radiation enteritis (12.2%), motility disorders (8.1%), and Crohn disease (5.4%).[19]

Occasionally, trauma that involves 1 or more of the major mesenteric vessels results in extensive bowel necrosis and short-bowel syndrome.

Leading pediatric and neonatal etiologies of short-bowel syndrome include necrotizing enterocolitis, multilevel small-bowel atresia, and midgut volvulus with ischemic bowel infarction.

In a study of 114 infants with jejunoileal atresia, Stollman et al found that surgical treatment (which included resection with primary anastomosis in 69% of the children and temporary enterostomy in 26% of them) resulted in short-bowel syndrome in 15% of the patients.[20] This led the investigators to suggest that short-bowel syndrome is the chief factor behind longer hospital stays for and increased feeding problems and rates of morbidity and mortality in infants who are surgically treated for jejunoileal atresia.



Estimates of the incidence and prevalence of short-bowel syndrome are difficult to make and, therefore, are rare. Most estimates are based on data describing patients requiring long-term home parenteral nutrition for short-bowel syndrome.

A report by Lennard-Jones estimated that in the United Kingdom, the incidence of short-bowel syndrome requiring such therapy was 2 patients per million population.[21]

Byrne et al estimated that in the United States, approximately 10,000-20,000 patients receive home-delivered TPN for short-bowel syndrome.[22]

Moreno and coworkers published data derived from the 2002 registry of patients receiving home-based parenteral nutrition in Spain.[19] The program had an enrollment of 74 patients, making the prevalence in Spain 1.8 patients per 1 million population.



At present, there is no reliable cure for short-bowel syndrome. Patients who are maintained on parenteral nutrition at home have reasonably good short-term outcomes. Data from Howard et al and Ladefoged et al revealed that the 4-year survival rate in patients who depend on parenteral nutrition is about 70%.[17, 23]

Eventually, many of these patients run out of venous access or have severe septic complications. Cost also is a major factor. Home parenteral nutrition costs range from about $50,000 to more than $200,000 per year. As mentioned before, the most common cause of death in these patients is liver failure.

The authors have reviewed the use and results of pharmacologic bowel compensation, including growth hormone, glutamine, and a high-carbohydrate diet. This may allow additional patients to be liberated from parenteral nutrition. The clinical results have been favorable, as described in earlier studies, but these results have not been reproduced at numerous medical centers.[24]

Nontransplant surgical procedures have been applied to short-bowel syndrome. Early results were mixed, but many of the procedures being performed then involved segment reversal. Subsequent series have demonstrated clinical improvement in more than 80% of patients. The most common operations performed in these series were intestinal tapering, intestinal lengthening, and strictureplasty. Even in these series, segment reversal and creation of artificial valves produced dubious results.

Organ transplantation is a promising therapeutic option but continues to be fraught with problems. Early postoperative mortality can be as high as 30%. Data from leading transplant centers have shown that the 1-year survival rates can be as high as 80-90%, and approximately 60% of patients are alive at 4 years.

Contributor Information and Disclosures

Burt Cagir, MD, FACS Clinical Professor of Surgery, The Commonwealth Medical College; Attending Surgeon, Assistant Program Director, Robert Packer Hospital; Attending Surgeon, Corning Hospital

Burt Cagir, MD, FACS is a member of the following medical societies: American College of Surgeons, American Medical Association, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.


Michael AJ Sawyer, MD Consulting Staff, Department of Surgery, Comanche County Memorial Hospital; Medical Director, Lawton Bariatrics

Michael AJ Sawyer, MD is a member of the following medical societies: American Society for Metabolic and Bariatric Surgery, Society for Surgery of the Alimentary Tract, Society of Laparoendoscopic Surgeons, American College of Surgeons, Society of American Gastrointestinal and Endoscopic Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

David L Morris, MD, PhD, FRACS Professor, Department of Surgery, St George Hospital, University of New South Wales, Australia

David L Morris, MD, PhD, FRACS is a member of the following medical societies: British Society of Gastroenterology

Disclosure: Received none from RFA Medical for director; Received none from MRC Biotec for director.

Chief Editor

John Geibel, MD, DSc, MSc, MA Vice Chair and Professor, Department of Surgery, Section of Gastrointestinal Medicine, and Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director, Surgical Research, Department of Surgery, Yale-New Haven Hospital; American Gastroenterological Association Fellow

John Geibel, MD, DSc, MSc, MA is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, Society for Surgery of the Alimentary Tract

Disclosure: Received royalty from AMGEN for consulting; Received ownership interest from Ardelyx for consulting.

Additional Contributors

Juan B Ochoa, MD Assistant Professor, Department of Surgery, University of Pittsburgh School of Medicine; Medical and Scientific Director, HCN, Nestle Healthcare Nutrition

Disclosure: Nothing to disclose.

  1. Weser E. Nutritional aspects of malabsorption: short gut adaptation. Clin Gastroenterol. 1983 May. 12(2):443-61. [Medline].

  2. Weih S, Kessler M, Fonouni H, Golriz M, Hafezi M, Mehrabi A, et al. Current practice and future perspectives in the treatment of short bowel syndrome in children-a systematic review. Langenbecks Arch Surg. 2011 Nov 22. [Medline].

  3. Efsen E, Jeppesen PB. Modern treatment of adult short bowel syndrome patients. Minerva Gastroenterol Dietol. 2011 Dec. 57(4):405-17. [Medline].

  4. Uchino M, Ikeuchi H, Bando T, Matsuoka H, Takahashi Y, Takesue Y, et al. Risk factors for short bowel syndrome in patients with Crohn's disease. Surg Today. 2011 Dec 17. [Medline].

  5. Wilmore DW, Dudrick SJ, Daly JM, et al. The role of nutrition in the adaptation of the small intestine after massive resection. Surg Gynecol Obstet. 1971 Apr. 132(4):673-80. [Medline].

  6. Wilmore DW, Dudrick SJ. Growth and development of an infant receiving all nutrients exclusively by vein. JAMA. 1968 Mar 4. 203(10):860-4. [Medline].

  7. Taha AM, Sharif K, Johnson T, Clarke S, Murphy MS, Gupte GL. Post Script: Long-Term Outcomes of Isolated Liver Transplantation For Short Bowel Syndrome And Intestinal Failure Associated Liver Disease. J Pediatr Gastroenterol Nutr. 2011 Dec 12. [Medline].

  8. Pansky B. Duodenum-jejunum-ileum, duodenal fossae, and superior mesenteric artery. Review of Gross Anatomy. 4th ed. New York, NY: Macmillan Publishing Co; 1979. 334-335.

  9. Starzl TE, Todo S, Tzakis A, et al. The many faces of multivisceral transplantation. Surg Gynecol Obstet. 1991 May. 172(5):335-44. [Medline].

  10. Sellin JH. Intestinal electrolyte absorption and secretion. Feldman M, Scharschmidt BF, Sleisinger MH. Sleisinger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 6th ed. Philadelphia, Pa: WB Saunders Co; 1998. 1451-1471.

  11. Clarke RM. Mucosal architecture and epithelial cell production rate in the small intestine of the albino rat. J Anat. 1970 Nov. 107:519-29. [Medline].

  12. Borgstrom B, Dahlquist A, Lundh G, et al. Studies of intestinal digestion and absorption in the human. J Clin Invest. 1957. 36:1521-1536.

  13. Johansson C. Studies of gastrointestinal interactions. VII. Characteristics of the absorption pattern of sugar, fat and protein from composite meals in man. A quantitative study. Scand J Gastroenterol. 1975. 10(1):33-42. [Medline].

  14. Phillips SF, Giller J. The contribution of the colon to electrolyte and water conservation in man. J Lab Clin Med. 1973 May. 81(5):733-46. [Medline].

  15. Pomare EW, Branch WJ, Cummings JH. Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest. 1985 May. 75(5):1448-54. [Medline].

  16. Sundaram A, Koutkia P, Apovian CM. Nutritional management of short bowel syndrome in adults. J Clin Gastroenterol. 2002 Mar. 34(3):207-20. [Medline].

  17. Ladefoged K, Hessov I, Jarnum S. Nutrition in short-bowel syndrome. Scand J Gastroenterol Suppl. 1996. 216:122-31. [Medline].

  18. Nightingale JM, Lennard-Jones JE. The short bowel syndrome: what's new and old?. Dig Dis. 1993. 11(1):12-31. [Medline].

  19. Moreno JM, Planas M, Lecha M, et al. [The year 2002 national register on home-based parenteral nutrition]. Nutr Hosp. 2005 Jul-Aug. 20(4):249-53. [Medline].

  20. Stollman TH, de Blaauw I, Wijnen MH, et al. Decreased mortality but increased morbidity in neonates with jejunoileal atresia; a study of 114 cases over a 34-year period. J Pediatr Surg. 2009 Jan. 44(1):217-21. [Medline].

  21. Lennard-Jones JE. Indications and need for long-term parenteral nutrition: implications for intestinal transplantation. Transplant Proc. 1990 Dec. 22(6):2427-9. [Medline].

  22. Byrne TA, Persinger RL, Young LS, et al. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg. 1995 Sep. 222(3):243-54; discussion 254-5. [Medline].

  23. Howard L, Ament M, Fleming CR, et al. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology. 1995 Aug. 109(2):355-65. [Medline].

  24. Wilmore DW, Byrne TA, Persinger RL. Short bowel syndrome: new therapeutic approaches. Curr Probl Surg. 1997 May. 34(5):389-444. [Medline].

  25. Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology. 1997 Nov. 113(5):1767-78. [Medline].

  26. Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000 Apr 4. 132(7):525-32. [Medline].

  27. Klein S, Nealon WH. Hepatobiliary abnormalities associated with total parenteral nutrition. Semin Liver Dis. 1988 Aug. 8(3):237-46. [Medline].

  28. Quigley EM, Marsh MN, Shaffer JL, et al. Hepatobiliary complications of total parenteral nutrition. Gastroenterology. 1993 Jan. 104(1):286-301. [Medline].

  29. Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Aug 5. [Medline].

  30. Gorczynski RM. Immunosuppression induced by hepatic portal venous immunization spares reactivity in IL-4 producing T lymphocytes. Immunol Lett. 1992 Jun. 33(1):67-77. [Medline].

  31. Cosnes J, Gendre JP, Evard D, et al. Compensatory enteral hyperalimentation for management of patients with severe short bowel syndrome. Am J Clin Nutr. 1985 May. 41(5):1002-9. [Medline].

  32. Scolapio JS, Fleming CR. Short bowel syndrome. Gastroenterol Clin North Am. 1998 Jun. 27(2):467-79, viii. [Medline].

  33. Booth IW. Enteral nutrition as primary therapy in short bowel syndrome. Gut. 1994 Jan. 35(1 Suppl):S69-72. [Medline].

  34. Carbonnel F, Cosnes J, Chevret S, et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN J Parenter Enteral Nutr. 1996 Jul-Aug. 20(4):275-80. [Medline].

  35. Nightingale JM, Lennard-Jones JE, Walker ER, et al. Jejunal efflux in short bowel syndrome. Lancet. 1990 Sep 29. 336(8718):765-8. [Medline].

  36. Woolf GM, Miller C, Kurian R, et al. Nutritional absorption in short bowel syndrome. Evaluation of fluid, calorie, and divalent cation requirements. Dig Dis Sci. 1987 Jan. 32(1):8-15. [Medline].

  37. Wilmore DW, Lacey JM, Soultanakis RP, et al. Factors predicting a successful outcome after pharmacologic bowel compensation. Ann Surg. 1997 Sep. 226(3):288-92; discussion 292-3. [Medline].

  38. Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012 Dec. 143(6):1473-1481.e3. [Medline].

  39. Van Gossum A, Cabre E, Hebuterne X, et al. ESPEN Guidelines on Parenteral Nutrition: gastroenterology. Clin Nutr. 2009 Aug. 28(4):415-27. [Medline].

  40. Wallis K, Walters JR, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care. 2009 Sep. 12(5):526-32. [Medline].

  41. Farthing MJ. Octreotide in dumping and short bowel syndromes. Digestion. 1993. 54 Suppl 1:47-52. [Medline].

  42. Thompson JS, Langnas AN, Pinch LW, et al. Surgical approach to short-bowel syndrome. Experience in a population of 160 patients. Ann Surg. 1995 Oct. 222(4):600-5; discussion 605-7. [Medline].

  43. Thompson JS, Langnas AN. Surgical approaches to improving intestinal function in the short-bowel syndrome. Arch Surg. 1999 Jul. 134(7):706-9; discussion 709-11. [Medline].

  44. Panis Y, Messing B, Rivet P, et al. Segmental reversal of the small bowel as an alternative to intestinal transplantation in patients with short bowel syndrome. Ann Surg. 1997 Apr. 225(4):401-7. [Medline].

  45. Javid PJ, Kim HB, Duggan CP, et al. Serial transverse enteroplasty is associated with successful short-term outcomes in infants with short bowel syndrome. J Pediatr Surg. 2005 Jun. 40(6):1019-23; discussion 1023-4. [Medline].

  46. Oliveira C, de Silva N, Wales PW. Five-year outcomes after serial transverse enteroplasty in children with short bowel syndrome. J Pediatr Surg. 2012 May. 47(5):931-7. [Medline].

  47. Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg. 1995 Sep. 222(3):270-80; discussion 280-2. [Medline].

  48. Langnas AN, Shaw BW Jr, Antonson DL, et al. Preliminary experience with intestinal transplantation in infants and children. Pediatrics. 1996 Apr. 97(4):443-8. [Medline].

  49. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May. 186(5):512-25; discussion 525-7. [Medline].

  50. Sudan D, Thompson J, Botha J, et al. Comparison of intestinal lengthening procedures for patients with short bowel syndrome. Ann Surg. 2007 Oct. 246(4):593-601; discussion 601-4. [Medline].

  51. Abu-Elmagd K, Fung J, Bueno J, et al. Logistics and technique for procurement of intestinal, pancreatic, and hepatic grafts from the same donor. Ann Surg. 2000 Nov. 232(5):680-7. [Medline].

  52. Fitzgibbons S, Ching YA, Valim C, et al. Relationship between serum citrulline levels and progression to parenteral nutrition independence in children with short bowel syndrome. J Pediatr Surg. 2009 May. 44(5):928-32. [Medline].

  53. Andorsky DJ, Lund DP, Lillehei CW, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001 Jul. 139(1):27-33. [Medline].

  54. Baldwin-Price HK, Copp D, Singleton AO Jr. Reversed intestinal segments in the management of anenteric malabsorption syndrome. Ann Surg. 1965 Feb. 161:225-30. [Medline].

  55. Benedetti E, Baum C, Cicalese L, et al. Progressive functional adaptation of segmental bowel graft from living related donor. Transplantation. 2001 Feb 27. 71(4):569-71. [Medline].

  56. Chen MK, Badylak SF. Small bowel tissue engineering using small intestinal submucosa as a scaffold. J Surg Res. 2001 Aug. 99(2):352-8. [Medline].

  57. Cicalese L, Baum C, Brown M, et al. Segmental small bowel transplant from adult living-related donors. Transplant Proc. 2001 Feb-Mar. 33(1-2):1553. [Medline].

  58. Cicalese L, Rastellini C, Sileri P, et al. Segmental living related small bowel transplantation in adults. J Gastrointest Surg. 2001 Mar-Apr. 5(2):168-72; discussion 173. [Medline].

  59. Dudrick SJ, Wilmore DW, Vars HM, et al. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery. 1968 Jul. 64(1):134-42. [Medline].

  60. Ellegard L, Bosaeus I, Nordgren S, et al. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg. 1997 Jan. 225(1):88-96. [Medline].

  61. Gerwig WH, Ghaphery A. Experimental attempt to delay alimentary transit after small bowel exclusion. Arch Surg. 1963. 87:50-57.

  62. Greenberger NJ. State of the art: the management of the patient with short bowel syndrome. Am J Gastroenterol. 1978 Nov. 70(5):528-40. [Medline].

  63. Howard L, Heaphey L, Fleming CR, et al. Four years of North American registry home parenteral nutrition outcome data and their implications for patient management. JPEN J Parenter Enteral Nutr. 1991 Jul-Aug. 15(4):384-93. [Medline].

  64. Høverstad T. Studies of short-chain fatty acid absorption in man. Scand J Gastroenterol. 1986 Apr. 21(3):257-60. [Medline].

  65. Kocoshis S. Evolving concepts and improving prospects for neonates with short bowel syndrome. J Pediatr. 2001 Jul. 139(1):5-7. [Medline].

  66. Kono K, Sekikawa T, Iizuka H, et al. Interposed colon between remnants of the small intestine exhibits small bowel features in a patient with short bowel syndrome. Dig Surg. 2001. 18(3):237-41. [Medline].

  67. Lennard-Jones JE. Review article: practical management of the short bowel. Aliment Pharmacol Ther. 1994 Dec. 8(6):563-77. [Medline].

  68. Lennard-Jones JE, Wood S. Coping with the short bowel syndrome. Hosp Update. 1991. 27:797-807.

  69. Li-Ling, Irving M. The effectiveness of growth hormone, glutamine and a low-fat diet containing high-carbohydrate on the enhancement of the function of remnant intestine among patients with short bowel syndrome: a review of published trials. Clin Nutr. 2001 Jun. 20(3):199-204. [Medline].

  70. Lord LM, Schaffner R, DeCross AJ, et al. Management of the patient with short bowel syndrome. AACN Clin Issues. 2000 Nov. 11(4):604-18. [Medline].

  71. Meyer D, Thorwarth WM, Otto C, et al. Orthotopic liver/small bowel transplantation in rats: a microsurgical model inducing tolerance. Microsurgery. 2001. 21(4):156-62. [Medline].

  72. Nehra V, Camilleri M, Burton D, et al. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol. 2001 May. 96(5):1494-8. [Medline].

  73. Pansky B. Pancreas. Review of Gross Anatomy. 4th ed. New York, NY: Macmillan Publishing Co; 1979. 332-333.

  74. Pansky B. Blood supply of the colon and appendix. Review of Gross Anatomy. 4th ed. New York, NY: Macmillan Publishing Co; 1979. 340-341.

  75. Pansky B. The large intestine. Review of Gross Anatomy. 4th ed. New York, NY: Macmillan Publishing Co; 1979. 338-339.

  76. Pansky B. Duodenum. Review of Gross Anatomy. 4th ed. New York, NY: Macmillan Publishing Co; 1979. 330-331.

  77. Pearson PY, O'Connor DM, Schwartz MZ. Novel effect of leptin on small intestine adaptation. J Surg Res. 2001 May 15. 97(2):192-5. [Medline].

  78. Pertsemlidis D, Kark AE. Antiperistaltic segments for the treatment of short bowel syndrome. Am J Gastroenterol. 1974 Dec. 62(6):526-30. [Medline].

  79. Ploeg RJ, D'Alessandro AM. Intestinal transplantation: a clinical update. Scand J Gastroenterol Suppl. 1995. 212:79-89. [Medline].

  80. Scolapio JS, McGreevy K, Tennyson GS, et al. Effect of glutamine in short-bowel syndrome. Clin Nutr. 2001 Aug. 20(4):319-23. [Medline].

  81. Sedgwick CE, Viglotti J. Hyperalimentation. Surg Clin North Am. 1971 Jun. 51(3):681-6. [Medline].

  82. Stern LE, Erwin CR, O'Brien DP, et al. Epidermal growth factor is critical for intestinal adaptation following small bowel resection. Microsc Res Tech. 2000 Oct 15. 51(2):138-48. [Medline].

  83. Tatsumi Y, Matis LA, Iramajiri K, et al. The molecular mechanism of the functional development of the TcR-gamma delta cells and the effects of cytokines. 9th Congr Immunology. 1995. 1499.

  84. Terra RM, Plopper C, Waitzberg DL, et al. Remaining small bowel length: association with catheter sepsis in patients receiving home total parenteral nutrition: evidence of bacterial translocation. World J Surg. 2000 Dec. 24(12):1537-41. [Medline].

  85. Thompson JS, Pinch LW, Young R, et al. Long-term outcome of intestinal lengthening. Transplant Proc. 2000 Sep. 32(6):1242-3. [Medline].

  86. Vanderhoof JA. Short bowel syndrome in children and small intestinal transplantation. Pediatr Clin North Am. 1996 Apr. 43(2):533-50. [Medline].

  87. Vernon AH, Georgeson KE. Surgical options for short bowel syndrome. Semin Pediatr Surg. 2001 May. 10(2):91-8. [Medline].

  88. Whang EE, Shen KR. Intestinal adaptation: a new era. JPEN J Parenter Enteral Nutr. 2001 Mar-Apr. 25(2):100. [Medline].

  89. Wilmore DW, Robinson MK. Short bowel syndrome. World J Surg. 2000 Dec. 24(12):1486-92. [Medline].

  90. Zhou X, Li YX, Li N, et al. Glutamine enhances the gut-trophic effect of growth hormone in rat after massive small bowel resection. J Surg Res. 2001 Jul. 99(1):47-52. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.